Program
Rocuronium
Also written as “Rocuronium bromide (Zemuron)”, “rocuronium” and “Rocuronium (0.6mg/kg)”.
Its studies are mostly in Patient Satisfaction, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 80 open or running | phase 4since Apr 2, 2015 | Jul 26, 2005 | none ahead |
| Amckaus PTY | 11 open or running | phase 2since Apr 20, 2026 | Apr 20, 2026 | Jun 30, 2027phase 2 · NCT07595393 |
| Dr. Horst Schmidt Klinik | 10 open or running | no phasesince Jul 9, 2013 | Jul 9, 2013 | none ahead |
| Medtronic | 10 open or running | no phasesince Sep 22, 2011 | Sep 22, 2011 | none ahead |
Also a collaborator on its studies: novotech-australia-pty-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2005First studies: 2 phase 3 studies in AnesthesiaNew to MerckMerck · NCT00124735, NCT00124722
- May 14, 20072 phase 3 studies in Anesthesia, GeneralMerck · NCT00473694, NCT00474253
- Oct 31, 2007Phase 2 study in Anesthesia, GeneralMerck · NCT00552617 · 100 enrolled
- Sep 10, 2008Phase 3 study in Neuromuscular BlockadeMerck · NCT00751179 · 161 enrolled
- Jul 23, 2009Phase 3 study in AnesthesiaMerck · NCT00970762 · 90 enrolled
- Sep 22, 2011Medtronic's first study: no phase study in AnesthesiaNew to MedtronicMedtronic · NCT01450813 · 80 enrolled · United States
- Jul 9, 2013Dr. Horst Schmidt Klinik's first study: no phase study in FasciculationNew to Dr. Horst Schmidt KlinikDr. Horst Schmidt Klinik · NCT01902641 · 105 enrolled · Germany
- Apr 2, 2015Phase 4 study in Neuromuscular BlockadeMerck · NCT02410590
- Apr 20, 2026Amckaus PTY's first study: phase 2 study in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia SurgeryNew to Amckaus PTYAmckaus PTY · NCT07595393 · 64 planned
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia SurgeryAmckaus PTY · NCT07595393
TargetBeta
“Muscle-type nicotinic acetylcholine receptor antagonist”ChEMBL 37, by rule
Other programs on the same 5 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| vecuroniumrule | Merck | phase 4 | 4 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07595393Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery | 2 | Not yet recruiting | Amckaus PTY | Jun 30, 2027 | 64 |
| NCT02410590Neuromuscular Blockade | 4 | Withdrawn | Merck | Oct 2016 | 0 |
| NCT01902641Fasciculation · Germany | – | Completed | Dr. Horst Schmidt Klinik | Mar 2012 | 105 |
| NCT01450813Anesthesia · United States | – | Completed | Medtronic | Dec 2013 | 80 |
| NCT00970762Anesthesia | 3 | Completed | Merck | Feb 2004 | 90 |
| NCT00751179Neuromuscular Blockade | 3 | Completed | Merck | Dec 2009 | 161 |
| NCT00552617Anesthesia, General | 2 | Completed | Merck | Aug 31, 2006 | 100 |
| NCT00474253Anesthesia, General | 3 | Completed | Merck | Aug 22, 2006 | 115 |
| NCT00473694Anesthesia, General | 3 | Completed | Merck | Nov 6, 2006 | 182 |
| NCT00124735Anesthesia | 3 | Completed | Merck | Aug 2007 | 149 |
| NCT00124722Anesthesia | 3 | Completed | Merck | Jul 2007 | 207 |
How it is read
Names in the registry
- “Rocuronium”, 4 entries
- “Rocuronium bromide (Zemuron)”, 3 entries
- “rocuronium”, 2 entries
- “Rocuronium (0.6mg/kg)”, 1 entry
- “Rocuronium 0.2 mg/kg”, 1 entry
Conditions, from the studies’ own filings
- Patient Satisfaction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.